Holen Sie sich die Stockscreener-App
1.39
6.11%
0.08
Handel nachbörslich:
1.35
-0.04
-2.88%
Schlusskurs vom Vortag:
$1.31
Offen:
$1.37
24-Stunden-Volumen:
333.72K
Relative Volume:
0.75
Marktkapitalisierung:
$43.58M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.00M
KGV:
-0.50
EPS:
-2.78
Netto-Cashflow:
$-55.26M
1W Leistung:
+9.45%
1M Leistung:
+4.51%
6M Leistung:
-74.35%
1J Leistung:
-80.20%
1-Tages-Spanne:
$1.26
$1.39
1-Wochen-Bereich:
$1.2002
$1.39
52-Wochen-Spanne:
$1.05
$10.16
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Firmenname
Acrivon Therapeutics Inc
Sektor
Branche
Telefon
617-207-8979
Adresse
480 ARSENAL WAY, SUITE 100, WATERTOWN
Vergleichen Sie ACRV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
1.39 | 41.08M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.30 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.97 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.73 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
652.43 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.69 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-05 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-01-31 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-12-15 | Fortgesetzt | Jefferies | Buy |
| 2023-10-05 | Eingeleitet | Maxim Group | Buy |
| 2023-06-02 | Eingeleitet | Oppenheimer | Outperform |
| 2023-05-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-04-27 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2023-04-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-12-12 | Eingeleitet | Cowen | Outperform |
| 2022-12-12 | Eingeleitet | Jefferies | Buy |
| 2022-12-12 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Acrivon Therapeutics Inc Aktie (ACRV) Neueste Nachrichten
Why Acrivon Therapeutics Inc. is moving todayJuly 2025 PreEarnings & Capital Efficient Trading Techniques - Newser
Oppenheimer Adjusts Acrivon Therapeutics Price Target to $8 From $9, Maintains Outperform Rating - MarketScreener
Using fundamentals and technicals on Acrivon Therapeutics Inc.2025 Technical Overview & Reliable Volume Spike Alerts - Newser
Best data tools to analyze Acrivon Therapeutics Inc. stock2025 Retail Activity & Community Verified Swing Trade Signals - Newser
How to integrate Acrivon Therapeutics Inc. into portfolio analysis toolsJuly 2025 Volume & Weekly Market Pulse Alerts - Newser
Is Acrivon Therapeutics Inc. stock a good hedge against inflationJuly 2025 Highlights & Verified Entry Point Signals - Newser
Why Acrivon Therapeutics Inc. stock attracts strong analyst attention2025 Market Trends & Weekly Market Pulse Updates - Newser
How Acrivon Therapeutics Inc. stock performs during market volatilityGap Up & Low Risk Entry Point Guides - Newser
Acrivon Therapeutics Reports Q2 2025 Financial Results - TipRanks
Acrivon Posts Narrower Loss in Q2 - Nasdaq
Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights - GlobeNewswire
Acrivon's Cancer Drug Pipeline Advances with Tumor Response in Endometrial Cancer Trials - Stock Titan
Using economic indicators to assess Acrivon Therapeutics Inc. potentialEarnings Summary Report & High Yield Equity Trading Tips - Newser
Is Acrivon Therapeutics Inc. stock entering bullish territory2025 Volatility Report & Safe Entry Momentum Tips - Newser
Understanding Acrivon Therapeutics Inc.’s price movementMarket Weekly Review & High Conviction Buy Zone Picks - Newser
Published on: 2025-08-13 05:35:41 - Newser
Acrivon Therapeutics, Inc. Receives Buy Rating Due to Promising Clinical Data and Strategic Trial Expansion - TipRanks
Leading vs lagging indicators on Acrivon Therapeutics Inc. performanceDaily Trade Setup Forecast with Confidence - Newser
Real time alert setup for Acrivon Therapeutics Inc. performanceStable Profit Zone and Loss Control Analysis - Newser
Statistical indicators supporting Acrivon Therapeutics Inc.’s strengthFree Triple Digit Return Stock Predictions - Newser
Short interest data insights for Acrivon Therapeutics Inc.Technical Reversal Pattern Summary and Tracker - Newser
Momentum divergence signals in Acrivon Therapeutics Inc. chartLoss Limitation Strategy Based on Analysis - Newser
How to recover losses in Acrivon Therapeutics Inc. stockFree AI Driven Stock Trend Forecast - Newser
Acrivon Therapeutics (ACRV) Expected to Announce Earnings on Tuesday - Defense World
What makes Acrivon Therapeutics Inc. stock price move sharplyTriple Digit Gain Opportunity Watchlist - Newser
Real time breakdown of Acrivon Therapeutics Inc. stock performanceAI Triggered Buy Zone Forecast System - Newser
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
How high can Acrivon Therapeutics Inc. stock price go in 2025Free Secure Return Focused Investment Plan - Newser
What moving averages say about Acrivon Therapeutics Inc.Early Entry Ideas with Momentum Potential - Newser
Tools to monitor Acrivon Therapeutics Inc. recovery probabilityFree Profit Target Stock Opportunity Monitor - Newser
Detecting support and resistance levels for Acrivon Therapeutics Inc.Trade Setup Builder with Custom Alerts - Newser
Will breakout in Acrivon Therapeutics Inc. lead to full recoveryRisk Balanced Picks for Safer Trading - Newser
Candlestick Reversal Detected on Acrivon Therapeutics Inc.’s ChartShort Term Buy Zone Stock Alerts Signal Entry - metal.it
Cantor Fitzgerald sets Acrivon stock to Overweight on AP3 platform - MSN
What institutional investors are buying Acrivon Therapeutics Inc. stockStrongest growth potential - Jammu Links News
When is Acrivon Therapeutics Inc. stock expected to show significant growthFree Consultation - Jammu Links News
Finanzdaten der Acrivon Therapeutics Inc-Aktie (ACRV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):